Surgical Oncology
Volume 15, Issue 1 , Pages 25-28 , July 2006

Lessons from Coley's Toxin

References 

  1. Coley WB. Contribution to the knowledge of sarcoma. Annals of Surgery. 1891;14:199–220
  2. Coley WB. Late results of the treatment of inoperable sarcoma by the mixed toxins of erysipelas and Bacillus prodigiosus. The American Journal of the Medical Sciences. 1906;131:375–430
  3. Starnes CO. Coley's Toxins in perspective. Nature. 1992;357:11–12
  4. Shear MJ, Turner FC. Chemical treatment of tumors: V. Isolation of the hemorrhage-producing fraction from Serratia marcescens (Bacillus prodigiosus) culture filtrate. Journal of the National Cancer Institute. 1943;4:81–97
  5. Wiemann B, Starnes CO. Coley's Toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacology & Therapeutics. 1994;64:529–564
  6. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proceedings of the National Academy of Sciences USA. 1975;72:3666–3670
  7. Old LJ. Tumor necrosis factor (TNF). Science. 1985;230:630–632
  8. Berendt MJ, North RJ, Kirstein DP. The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell-mediated immunity. Journal of Experimental Medicine. 1978;148:1550–1559
  9. Berendt MJ, North RJ, Kirstein DP. The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant anti-tumor immunity. Journal of Experimental Medicine. 1978;148:1560–1569
  10. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science. 1997;278:1623–1626
  11. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. Journal of Immunology. 1994;153:1697–1706
  12. Zou JP, Yamamoto N, Fujii T, Takenaka H, Kobayashi M, Herrmann SH, et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. International Immunology. 1995;7:1135–1145
  13. Tsung K, Meko JB, Tsung YL, Peplinski GR, Norton JA. Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12. Journal of Immunology. 1998;160:1369–1377
  14. Le HN, Lee NC, Tsung K, Norton JA. Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12. Journal of Immunology. 2001;167:6765–6772
  15. Iwasaki M, Yu WG, Uekusa Y, Nakajima C, Yang YF, Gao P, et al. Differential IL-12 responsiveness of T cells but not of NK cells from tumor-bearing mice in IL-12-responsive versus-unresponsive tumor models. International Immunology. 2000;12:701–709
  16. Tsung K, Dolan JP, Tsung YL, Norton JA. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Research. 2002;62:5069–5075
  17. Tsung K, Meko JB, Peplinski GR, Tsung YL, Norton JA. IL-12 induces T helper 1-directed antitumor response. Journal of Immunology. 1997;158:3359–3365
  18. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity. 1994;1:447–456
  19. North RJ, Bursuker I. Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1–2+ effector T cells. Journal of Experimental Medicine. 1984;159:1295–1311
  20. D’Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M, et al. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. Journal of Experimental Medicine. 1992;176:1387–1398
  21. Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. Journal of Immunology. 1995;154:5071–5079
  22. Wysocka M, Kubin M, Vieira LQ, Ozmen L, Garotta G, Scott P, et al. Interleukin-12 is required for interferon-gamma production and lethality in lipopolysaccharide-induced shock in mice. European Journal of Immunology. 1995;25:672–676
  23. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. Journal of Immunology. 1999;163:5211–5218
  24. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Research. 1999;59:3128–3133
  25. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. European Journal of Immunology. 2004;34:336–344
  26. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Research. 1998;58:3491–3494
  27. Schumacher K, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Research. 2001;61:3932–3936
  28. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New England Journal of Medicine. 2003;348:203–213
  29. Marth C, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Doppler W, et al. Interferon-gamma expression is an independent prognostic factor in ovarian cancer. American Journal of Obstetrics and Gynecology. 2004;191:1598–1605
  30. Saleh FH, Crotty KA, Hersey P, Menzies SW. Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1. International Journal of Cancer. 2001;94:551–557
  31. Iwamoto M, Shinohara H, Miyamoto A, Okuzawa M, Mabuchi H, Nohara T, et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. International Journal of Cancer. 2003;104:92–97
  32. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411:380–384

PII: S0960-7404(06)00021-1

doi: 10.1016/j.suronc.2006.05.002

Surgical Oncology
Volume 15, Issue 1 , Pages 25-28 , July 2006

Article Tools